Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, announced a strategic initiative to explore ibogaine-based therapeutics for traumatic brain injury (TBI) and related neuropsychiatric conditions. The company has filed a provisional U.S. patent application covering compositions and methods using ibogaine and related compounds to treat TBI, PTSD, and associated disorders.
The move marks a significant expansion of Silo Pharma's pipeline into the underserved area of TBI, which affects millions globally and currently lacks effective pharmacological treatments. By targeting the neuropsychiatric sequelae of TBI, including PTSD, the company aims to address a critical unmet medical need. Ibogaine, a naturally occurring psychoactive compound, has shown promise in preclinical studies for neuroprotection and neuroplasticity, making it a candidate for TBI therapy.
Silo Pharma's therapeutic focus is on underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The company's portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. Research is conducted in collaboration with leading universities and laboratories.
The announcement follows the company's strategy to leverage existing research on ibogaine's effects on the brain. The provisional patent application underscores Silo's commitment to intellectual property protection in this emerging therapeutic area. According to the company, the initiative could open new avenues for treating TBI and related conditions that currently have limited options.
For more details on the initiative, the full press release is available at https://ibn.fm/HdWHG. Additional information about Silo Pharma and its pipeline can be found on its website at silopharma.com. Investors can access the latest news and updates regarding SILO in the company's newsroom at https://ibn.fm/SILO.
